Nanosystems for early Diagnosis of Neurodegenerative Diseases (NADINE)

nadine logo

Reference: CP-IP 246513-2

Funded by: European Commission

Official website of the project:

Period: 01/09/2010 – 3/08/2015

Program: FP7 -NMP-2009-4.0-3 – Development of nanotechnology-based systems for molecular diagnostics and imaging

Partners: Fundación Privada Institut Català de Nanotecnologia (ICN), Danmarks Tekniske Universitet, (DTU-Nanotech), Université Paris-Sud xI, Univerzita Pardubice, Ustav Makromolekulami Chemie AV CR, Institut Curie, Centre National
de la Recerche Scientifique, Universität ULM, Universitätsklinikum Essen, DiagnoSwiss SA, Fluigent SA, Moravian-Biotechnology (S.P.O.L.-S.R.O.), Kungliga Tekniska Högskolan,
Ita-Suomen Yliopisto, Instituto di Chimica di Riconoscimento Molecolare, Association pour la Recherche et le Développement, Ecole Nationale Supérieure des Mines de Paris, Ramboll Denmark AS


Medical diagnosis is currently undergoing a major revolution due to the fast discovery of molecular biomarkers, and the development of multimodal “metabiomarker” signatures. Progress, however, is hindered by the low abundance of many biomarkers of interest in body fluids, in absolute concentration and with regard to other biomolecules. The aim of the NADINE project is to apply progresses in biotechnology, nanoparticle synthesis, and nano-instrumentation to the development of fully integrated lab-on chip instruments able to perform elaborate multimodal biomarker analysis on a routine basis and at the ultrasensitive level required to allow minimally invasive tests.

In particular, we aim at overcoming a major bottleneck on the path to this objective, which was identified in a previous project in the “HEALTH” priority: no satisfactory solution currently exists to bridge the several orders of magnitude difference between the nanoscale volumes at which ultrasensitive new generation sensors operate, and the often millilitre volumes of samples in which the molecules of interest must be found. For this, we shall combine innovations in pre-concentration, micro and nanofluidics, self-assembly, micro-nanofabrication, and nanodetection.

The project will develop a generic, multipurpose, platform of compatible enabling technologies, and integrate them into an automated device. In order to maximize impact and societal benefit, the project will be validated on the early detection of biomarkers for neurodegenerative diseases, notably Alzheimer, and subtyping of these diseases for improved treatment strategies. The project involves a multidisciplinary consortium of technology developers, three leading biomedical groups in clinical neuroscience for definition of specifications and end-user pre-clinical validation, three researchoriented SMEs in biotechnology, nanosensing and microfluidics and a pharmaceutical company.